论文部分内容阅读
目的 观察抗肿瘤药去甲长春花碱 (Navelbine ,NVB) +顺铂 (cisplatin ,DDP)联合治疗晚期非小细胞肺癌(Nonsmallcelllungcancer ,NSCLC)的疗效、不良反应及生存期。 方法 符合入选条件的Ⅲ～Ⅳ期NSCLC患者 10 6例 ,男 80例 ,女 2 6例 ,其中腺癌 63例 ,鳞癌 3 9例 ,混合细胞型 4例。治疗方案NVB 3 0mg/m2 ivd1,8;DDP 2 5mg/m2 ivd1～3或 70mg/m2 ivd1。 2 1天为一周期 ,每 3周重复一次 ,每例至少用 2个周期。全组病例随访 1～ 3年 ,随访率 98%。结果 CR 3例 ,PR 44例 ,SD 44例 ,PD 15例 ,总有效率 44 .3 4% (4 7/10 6)中位缓解期 7.5个月 (3 .5～ 12个月 ) ,中位生存期 10个月 (4～ 3 6个月 )。不良反应 :主要是Ⅱ～Ⅲ度白细胞下降 ,轻度的胃肠道反应及少数局部静脉炎。结论 NVB+DDP联合治疗晚期NSCLC疗效佳、毒副反应可耐受 ,且能延长患者生存期 ,是一个值得推广的治疗方案。
Objective To observe the efficacy, adverse reactions and survival of anti-tumor drug combination of Navelbine (NVB) + cisplatin (DDP) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods A total of 106 patients with stage III-IV NSCLC, including 80 males and 26 females, were enrolled. Among them, 63 were adenocarcinoma, 39 were squamous cell carcinoma and 4 were mixed cell type. Treatment regimen NVB 3 0 mg / m2 ivd1,8; DDP 2 5 mg / m2 ivd1-3 or 70 mg / m2 ivd1. 2 1 day cycle, repeated every 3 weeks for at least 2 cycles in each case. All cases were followed up for 1 to 3 years, the follow-up rate was 98%. Results CR 3 cases, 44 cases of PR, 44 cases of SD, 15 cases of PD, the total effective rate was 44.34% (47/106), the median remission period was 7.5 months (3.5 to 12 months) Bit survival of 10 months (4 ~ 36 months). Adverse reactions: mainly Ⅱ ~ Ⅲ degree leukopenia, mild gastrointestinal reactions and a small number of local phlebitis. Conclusion NVB + DDP combined with advanced NSCLC has good curative effect, tolerable side effects and prolonged survival. It is a worthy promotion treatment.